These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29387734)

  • 1. Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD.
    Wallace LM; Saad NY; Pyne NK; Fowler AM; Eidahl JO; Domire JS; Griffin DA; Herman AC; Sahenk Z; Rodino-Klapac LR; Harper SQ
    Mol Ther Methods Clin Dev; 2018 Mar; 8():121-130. PubMed ID: 29387734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy.
    Wallace LM; Liu J; Domire JS; Garwick-Coppens SE; Guckes SM; Mendell JR; Flanigan KM; Harper SQ
    Mol Ther; 2012 Jul; 20(7):1417-23. PubMed ID: 22508491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designed U7 snRNAs inhibit 
    Rashnonejad A; Amini-Chermahini G; Taylor NK; Wein N; Harper SQ
    Mol Ther Nucleic Acids; 2021 Mar; 23():476-486. PubMed ID: 33510937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD.
    Giesige CR; Wallace LM; Heller KN; Eidahl JO; Saad NY; Fowler AM; Pyne NK; Al-Kharsan M; Rashnonejad A; Chermahini GA; Domire JS; Mukweyi D; Garwick-Coppens SE; Guckes SM; McLaughlin KJ; Meyer K; Rodino-Klapac LR; Harper SQ
    JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA interference improves myopathic phenotypes in mice over-expressing FSHD region gene 1 (FRG1).
    Wallace LM; Garwick-Coppens SE; Tupler R; Harper SQ
    Mol Ther; 2011 Nov; 19(11):2048-54. PubMed ID: 21730972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
    Gatica LV; Rosa AL
    Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD).
    Ansseau E; Vanderplanck C; Wauters A; Harper SQ; Coppée F; Belayew A
    Genes (Basel); 2017 Mar; 8(3):. PubMed ID: 28273791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.
    van den Heuvel A; Mahfouz A; Kloet SL; Balog J; van Engelen BGM; Tawil R; Tapscott SJ; van der Maarel SM
    Hum Mol Genet; 2019 Apr; 28(7):1064-1075. PubMed ID: 30445587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle.
    Banerji CRS; Panamarova M; Hebaishi H; White RB; Relaix F; Severini S; Zammit PS
    Nat Commun; 2017 Dec; 8(1):2152. PubMed ID: 29255294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy.
    Bao B; Maruyama R; Yokota T
    Intractable Rare Dis Res; 2016 Aug; 5(3):168-76. PubMed ID: 27672539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of AAV Vectors for Delivery of RNAi.
    Borel F; Mueller C
    Methods Mol Biol; 2019; 1950():3-18. PubMed ID: 30783965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense targeting of 3' end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach.
    Marsollier AC; Ciszewski L; Mariot V; Popplewell L; Voit T; Dickson G; Dumonceaux J
    Hum Mol Genet; 2016 Apr; 25(8):1468-78. PubMed ID: 26787513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facioscapulohumeral muscular dystrophy.
    Tawil R
    Handb Clin Neurol; 2018; 148():541-548. PubMed ID: 29478599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNAscope in situ hybridization-based method for detecting
    Amini Chermahini G; Rashnonejad A; Harper SQ
    RNA; 2019 Sep; 25(9):1211-1217. PubMed ID: 31209064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy.
    Feng Q; Snider L; Jagannathan S; Tawil R; van der Maarel SM; Tapscott SJ; Bradley RK
    Elife; 2015 Jan; 4():. PubMed ID: 25564732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic zebrafish model of DUX4 misexpression reveals a developmental role in FSHD pathogenesis.
    Pakula A; Lek A; Widrick J; Mitsuhashi H; Bugda Gwilt KM; Gupta VA; Rahimov F; Criscione J; Zhang Y; Gibbs D; Murphy Q; Manglik A; Mead L; Kunkel L
    Hum Mol Genet; 2019 Jan; 28(2):320-331. PubMed ID: 30307508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.
    Dmitriev P; Bou Saada Y; Dib C; Ansseau E; Barat A; Hamade A; Dessen P; Robert T; Lazar V; Louzada RAN; Dupuy C; Zakharova V; Carnac G; Lipinski M; Vassetzky YS
    Free Radic Biol Med; 2016 Oct; 99():244-258. PubMed ID: 27519269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alleviation of off-target effects from vector-encoded shRNAs via codelivered RNA decoys.
    Mockenhaupt S; Grosse S; Rupp D; Bartenschlager R; Grimm D
    Proc Natl Acad Sci U S A; 2015 Jul; 112(30):E4007-16. PubMed ID: 26170322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facioscapulohumeral Muscular Dystrophies.
    Wagner KR
    Continuum (Minneap Minn); 2019 Dec; 25(6):1662-1681. PubMed ID: 31794465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. β-Catenin is central to DUX4-driven network rewiring in facioscapulohumeral muscular dystrophy.
    Banerji CR; Knopp P; Moyle LA; Severini S; Orrell RW; Teschendorff AE; Zammit PS
    J R Soc Interface; 2015 Jan; 12(102):20140797. PubMed ID: 25551153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.